Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer

TA61 Colorectal cancer - capecitabine and tegafur uracil: summary information

TA61 Colorectal cancer - capecitabine and tegafur uracil: summary (PDF 22 KB)

Colorectal cancer - capecitabine and tegafur uracil: review decision - June 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 60 KB)

Colorectal cancer - capecitabine and tegafur uracil: review proposal - April 2011 information

Appendix A - provisional matrix of stakeholders (PDF 70 KB)

Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 478 KB)

Review decision information

Review proposal (PDF 25 KB)

Assessment Report: A review of the evidence for the clinical and cost effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer (PDF 604 KB)

Final Appraisal Determination - Capecitabine and tegafur with uracil for metastatic colorectal cancer information

Final Appraisal Determination - Capecitabine and tegafur with uracil for metastatic colorectal cancer (PDF 207 KB)

Appraisal Consultation Document: Capecitabine and tegafur with uracil for metastatic colorectal cancer information

Assessment Report: A review of the evidence for the clinical and cost effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer (PDF 604 KB)

Final Scope: Appraisal of Capecitabine and tegafur with uracil for metastatic colorectal cancer information

Final Assessment Report protocol: Appraisal of Capecitabine and tegafur with uracil for metastatic colorectal cancer information

Protocol: A review of the evidence for the clinical and cost effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer (PDF 171 KB)